Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639284 | 0.85 | CYP2D6 (0.42) | LMNAGAAADRB2ADRB1AOC3 | |
| SCHEMBL1923705 | 0.83 | TDP1 (0.37) | LMNAKCNH2CYP51A1 | |
| SCHEMBL27023517 | 0.79 | TSHR (0.38) | GAA | |
| SCHEMBL23489766 | 0.79 | GAA (0.39) | GAAADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL17318479 | 0.79 | GAA (0.39) | GAAADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL31473883 | 0.79 | GAA (0.39) | GAAADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL9846960 | 0.78 | GAA (0.39) | LMNAGAAADRB2ADRB1AOC3 | |
| SCHEMBL22942074 | 0.77 | ADRB2 (0.63) | LMNAADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL31651702 | 0.76 | GAA (0.43) | LMNAGAAAOC3CYP2D6CYP3A4 | |
| SCHEMBL5700259 | 0.76 | GAA (0.43) | LMNAGAAAOC3CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230365543-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365543-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11673884-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | Foresee Pharmaceuticals Co., Inc. (TW) | 2023-06-13 | — | — | US | disclosed |
| US-11673884-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | Foresee Pharmaceuticals Co., Inc. (TW) | 2023-06-13 | — | — | US | disclosed |
| US-20230014855-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-20230365543-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-11673884-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | LMNA 1238/4885GAA 942/4885ADRB2 1993/4885 |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-20230014855-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | LMNA 1226/4885GAA 3247/4885ADRB2 4798/4885 |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LMNA 1041/4885GAA 785/4885ADRB2 1976/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | LMNA 1226/4885GAA 3247/4885ADRB2 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.